ABSTRACT We previously demonstrated improvements of colonic lesions due to dextran sulfate sodium (DSS) in rats after 7 d of supplementation with resistant starch (RS) type 3, a substrate yielding high levels of butyrate (C 4 ), a colonic cell fuel source. In the present study, we hypothesized that if inflammation is related to decreased C 4 utilization by the colonic mucosa, RS supplementation should restore C 4 use simultaneously with an increase in the amount of C 4 present in the digestive tract. Hence, we compared, in vivo, the cecocolonic uptake of C 4 and its oxidation into CO 2 and ketone bodies in control and DSS-treated rats fed a fiber-free basal diet (BD) or a RS-supplemented diet. Sprague-Dawley rats (n ϭ 60) were used. DSS treatment was performed to induce acute colitis and then to maintain chronic colitis. After cecal infusion of [1-
As end products of the anaerobic colonic fermentation of carbohydrates, the SCFA, mainly acetate, propionate, and butyrate, play a vital role in maintenance of colonic integrity and metabolism. Among them, butyrate (C 4 ) 2 apparently has trophic properties for the healthy or injured colonic epithelium (1-3), although some data are conflicting (4) . In vitro studies demonstrated that C 4 also is the preferred energyproviding substrate for colonic cells (5) (6) (7) . The pool of acetylCoA, resulting from the ␤-oxidation pathway of C 4 in the colonocyte, is oxidized into CO 2 and ketone bodies (KB), acetoacetate (AA) and ␤-hydroxybutyrate (BHB), via the hydroxy-methyl-glutaryl CoA pathway (Fig. 1) . Lipogenesis (9) , histone acetylation (10, 11) , detoxification of xenobiotics (12, 13) , and mucus synthesis (14) depend upon C 4 metabolism [and to a lesser degree, upon propionate metabolism (10, 14) ]. Moreover, C 4 is able to prevent the development of abnormal colonocytes more efficiently than propionate and acetate (15).
Butyrate is of great importance for colonic epithelial health because a lack of C 4 can result in intestinal inflammation (16) .
Rectal instillation of a specific chemical inhibitor of ␤-oxidation induces an acute colitis in rats (17) . It was suggested that abnormalities in C 4 oxidation may be involved in the pathogenesis of mucosal inflammation such as ulcerative colitis (UC) (18) . The effects of the inflammation process on C 4 utilization are well documented in vitro (18,19 -22) but not frequently in vivo (23, 24) . The decrease of C 4 oxidation into CO 2 observed during acute inflammatory lesions (16, 20, 22) tends to regress (18, 21, 23) or even disappear (19, 24) during chronic phases. Nevertheless, in vivo data obtained by measurements of 13 CO 2 (24) or 14 CO 2 (23) in exhaled breath after 13 C 4 or 14 C 4 enemas in patients suffering from UC, give a relatively indirect estimation of C 4 colonic oxidation because part of the labeled exhaled CO 2 could originate from C 4 hepatic oxidation. The few results available on C 4 oxidation into KB (18, 22) indicated a decreased oxidation in vitro in inflamed colonocytes (18, 22) Consequently, in the present study, we examined the in vivo C 4 oxidation into CO 2 and KB by the colonic mucosa in a previously validated (25) experimental model of colitis and after [1- 13 C]-C 4 cecal infusions. The colitis was induced by continuous administration of dextran sulfate sodium (DSS) in water and characterized by macroscopical and histological observations (25) . This model allowed us to show that a diet containing resistant starch (RS) type 3 induced significant improvements of cecocolonic injuries (26) . The selected RS source (Novelose 330, by National Starch) was a pure nongranular retrograded starch devoid of any other macroconstituents with 50 g/100 g of total dietary fiber as measured by the AOAC method (27) and a small intestinal digestibility of ϳ50% in humans (28) . The healing effect of RS observed on DSS colitis seemed to be linked in part to SCFA and particularly C 4 production (24) . Therefore, we hypothesized that the greater the amount of available C 4 , the more it would be used by the inflamed mucosa for its energy requirements (29) . We also hypothesized that acute and chronic DSS inflammation would impair C 4 uptake and both of its oxidation pathways, and that the healing effect of RS is a consequence of an increase in C 4 disposal that should restore C 4 use for the colonic mucosa.
MATERIALS AND METHODS
Animals, diets, and housing. This experiment was approved by the Ethics Committee for Laboratory Animals (hosted by the National Veterinary School of Nantes) and conducted according to the French animal welfare rules (Decree no. 87-848, 19 October 1987). Male Sprague-Dawley rats (n ϭ 60; Harlan), weighing 310 Ϯ 10 g at arrival were used. They were housed individually in cages and had free access to food and water until killed. A light:dark cycle from 0800 -2000 h and 2000 -0800 h, respectively, was used. Two different diets were specially formulated for the experiment (INRA) ( Table 1) . The basal diet (BD) was a low-fiber diet (only 2 g/100 g cellulose), whereas the RS-supplemented diet was formulated by substituting 6.0 g/100 g of RS type 3 (retrograded Hylon 7, high amylo-cornstarch; Novelose 330, National Starch and Chemical) for pregelatinized cornstarch included in the basal diet. Diets were formulated to provide 6.0 g/100 g of indigestible carbohydrates in addition to cellulose on a dry matter basis. Body weight, water, and food intakes were recorded daily.
Induction of colitis. After 7 d of adaptation to both the diet and housing conditions, rats were randomly divided into two groups. The first group (DSS group) was administered a 50 g/L solution of DSS (MW ϭ 36 -44 kDa, ICN Pharmaceuticals) in water for 7 d to rapidly induce acute colitis (DSS-acute group). As described in a previous paper (25) , injuries were characterized histologically and typical lesions were noted, i.e., ulcerations, infiltrate rich in neutrophils and eosinophils, edema and crypt abscesses, vascular congestion, loss of goblet cells, and focal ischemic lesions (25) . The dose of DSS was then reduced to 30 g/L for 7 (DSS-chronic 7) or 14 d (DSS-chronic 14) to maintain the inflammation into a stable chronic active phase. These types of lesions were described previously, and histological analysis revealed severe disruption of tissue architecture, exulcerations, shifting of the submucosal edema in muscularis mucosae localization associated with an inflammatory infiltrate rich in lymphocytes (25) . The control group was not administered DSS at any point.
During the adaptation period and the 7 d of 50 g/L DSS treatment (induction of acute colitis), rats were fed BD (Fig. 2) . Then, during the 30 g/L DSS treatment period, rats were fed either BD or RS for 7 or 14 d creating 5 DSS groups: DSS-acute, BD-DSS chronic 7, RS-DSS chronic 7, BD-DSS chronic 14, and RS-DSS chronic 14 (n ϭ 6 in each group of rats). Corresponding control groups of 6 rats were also killed at each point of the protocol.
Cecal, proximal, and distal inflammatory injuries were assessed 6 Calculations were based using ME values of 16.72 kJ/g DM for pregelatinized cornstarch, casein, and DL-methionine, 37 .62 kJ/g DM for refined corn oil and lard, and 11.08 kJ/g DM for resistant starch according to the provider.
without knowledge of the treatment according to a macroscopic score described by Appleyard and Wallace (30) . The macroscopic score (maximum score 16) was the sum of partial scores assessing tissue adhesions, cecal mucosa, ulceration, diarrhea, blood in contents, and the colonic mucosa thickening. We showed previously that this score represented a good marker of the severity of the inflammation as well as mucosal healing (25) .
13 C 4 infusion and collection of samples. After anesthetization by i.p. injection of 1.5 mg/100 g xylazine (Bayer Pharma) and i.m. injection of 5.5 mg/100 g ketamine (Mérial), rats were laparotomized. A 20 mmol/L infusion of [1- 13 C] butyric acid (sodium salt, Mass Trace) was performed in the cecum for 1 h with a continuous flow of 1 mL/h delivered by a peristaltic pump (Ismatec SA). Infusion parameters (tracer concentration and infusion duration) were defined to establish an isotopic equilibrium in the portal blood before isotopic measurements. The infusion solution was prepared with sterile water for medical irrigation (B Braun) and osmolarity was adjusted to 300 mOsmol/L. The pH was adjusted to 6.0 using hydrochloric acid (Sigma-Aldrich) before infusion. During the cecal infusion, rats were kept under thermic covers. Portal blood flows were recorded continuously from 30 to 60 min of the infusion with a 2-mm Transonic blood-flow probe (Transonic Systems) around the portal vein. The mean portal blood flow was then calculated for at least 20 min.
After 1 h of infusion, blood samples were collected by venipuncture in the portal vein and in the abdominal aorta with an infusion set (0.4 mm o.d., 27-gauge, 17 mm length; Microflex). Rats were then killed with a 2-mL lethal intracardiac injection of sodium pentobarbital (Vetoquinol).
Measurements of butyrate and ketone bodies. Isotopic 13 Cenrichment and concentrations of butyrate, AA and BHB were measured simultaneously by GC-MS using an analytical procedure we described previously (31) . Ketone bodies (AA and BHB) originating from [1- 13 C] butyric acid could be enriched on none, one (position 1 or 3) or two (position 1 and 3) carbon atoms. Therefore we quantified only ketone bodies (AA and BHB) enriched on none, one or two carbon atoms.
Measurement of isotopic enrichment of 13 CO 2 in blood samples. Portal and arterial blood (300 L) was transferred into a 10-mL evacuated blood collection tube, and atmospheric pressure was reestablished with the addition of helium before slight agitation for 2 h. The gaseous phase was then transferred into a Labco Exetainer system (Labcolimited) and the 13 CO 2 enrichment was determined by GC/ isotope ratio MS (BreathMat, Finnigan). Total blood CO 2 concentration was measured using an IRMA Blood Analysis System (Diametrics Medical).
SCFA measurements in digestive contents. When rats were killed, representative fractions of the cecocolonic contents were removed and processed as previously described (26) . Acetate, propionate, and butyrate were quantified by GC (32) (GC-6890, HewlettPackard) using 2-ethylbutyric acid as the internal standard.
Calculations and statistics C 4 uptake. The uptake of digestive C 4 by the cecocolonic mucosa was as follows: The portal ⌬ 12 C 4 ϩ 13 C 4 flux, expressed in mol/min, was calculated by multiplying the arteriovenous difference (⌬) of the 12 C 4 and 13 C 4 concentrations (mol/mL) by the mean portal blood flow (mL/ min).
The infused 13 C 4 flux (mol/min) was obtained by dividing the amount of infused 13 C 4 (mol) by the infusion duration (min). Tracer purity was theoretically 99%. Nevertheless, 13 C-enrichment of each infusion solutions was systematically checked and, infused 13 12 C molecular ion and (M ϩ 1) the intensity of the 13 C isotopic molecular ion] given by the MS detector for the butyrate corresponded to the ratio (R) of 13 C 4 flux to the sum of 13 C 4 and 12 C 4 fluxes. Calculated with a pool of noninfused rats (6 fed the BD and 6 fed the RS diet), R 1 was determined as follows before the infusion:
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Isotopic enrichment of CO 2 . Based on the enrichment of blood samples (␦ sa ‰) given by the isotope ratio MS and on the ratio of 13 C to 12 C of the international PDB standard (␦ PDB ϭ 0.0112372), the isotopic enrichment of CO 2 was expressed in terms of atom % (AP) using the following formula (33):
Then, the isotopic enrichments of CO 2 in blood samples were calculated in AP excess (APE) as below: APE ϭ AP sample Ϫ AP basal Because of the low blood quantity available in rats, no blood sample representing time 0 was performed before infusion. Basal values were taken from the pool of healthy rats (6 fed the BD and 6 fed the RS diet). Arteriovenous difference (⌬) of APE were determined as follows:
All results were expressed as means Ϯ SEM, n ϭ the number of rats. Data were analyzed by 3-way ANOVA with treatment (DSS and control), diet (BD and RS), and time (chronic 7 and chronic 14) as main factors. To analyze the acute colitis data, a 1-way ANOVA was used with treatment (DSS or control) as the factor tested. When differences between means were significant, they were compared by contrasts analysis (Super Anova V.1.11, Abacus Concepts). Differences were considered significant at P Ͻ 0.05. 
RESULTS
Food and water consumption and relative body weight gain. During the first 7 d of the experiment (corresponding to the induction of the acute phase of the colitis for the DSStreated rats), food and water intake were 12.6 Ϯ 0.6 and 14.3 Ϯ 0.9 g/d, respectively, for DSS rats and 15.9 Ϯ 0.5 and 17.1 Ϯ 1.0 g/d, respectively, for control rats. Food and water intakes for the BD-DSS chronic 7, RS-DSS chronic 7, BD-DSS chronic 14 and RS-DSS chronic 14 rats are detailed in Table  2 . The water to food intake ratio did not differ between the DSS and control groups (data not shown).
Calculated from the beginning of the study to the time of killing, the relative body weight gain (RBWG) was -0.08 Ϯ 0.02 for DSS-acute rats and 0.04 Ϯ 0.01 for the corresponding controls (P ϭ 0.002). The RBWG of the control and DSS chronic 7 and chronic 14 rats are included in Table 2 .
Macroscopic score. The macroscopic scores of all of the control groups were zero. Values were 11.7 Ϯ 1.1 in DSS-acute rats. Macroscopic scores of DSS rats fed the RS diet were significantly lower than BD-DSS rats: 5.2 Ϯ 1.3 in RS-DSS rats vs. 10.8 Ϯ 0.9 in BD-DSS rats after 7 d of supplementation (P ϭ 0.0004) and 5.5 Ϯ 0.8 in RS-DSS rats vs. 8.7 Ϯ 0.6 in BD-DSS-chronic 14 rats (P ϭ 0.0286) (Fig. 3) .
SCFA measurements in digestive contents. The dietary treatment affected the total SCFA contents in DSS-rats (RS-DSS chronic 7 vs. BD-DSS chronic 7: P ϭ 0.0001; RS-DSS chronic 14 vs. BD-DSS chronic 14: P ϭ 0.0046). The contents of C 4 (as well as total SCFA) were greater in rats fed the RS diet than in those fed the BD diet (Table 3) .
Cecocolonic uptake and oxidation of C 4 . In the chronic study, regardless of the diet, the treatment, and the time of killing, portal blood flows and 13 C 4 infused flux did not differ between groups: 7.87 Ϯ 0.55 and 7.65 Ϯ 0.55 mL/min for portal blood flows, and, 0.38 Ϯ 0.02 and 0.35 Ϯ 0.02 mol/ min for 13 C 4 infused flux for controls and DSS rats, respectively (n ϭ 30 rats per group).
Acute colitis. The calculated digestive 12 C 4 flux did not differ between the DSS-acute group (0.48 Ϯ 0.07 mol/min) and control rats (0.45 Ϯ 0.06 mol/min). Nevertheless, the colonic butyrate metabolism was altered, as shown in Table 4 , i.e., the ⌬ 13 C 4 portal flux was greater in the DSS-acute group compared with the control group. Simultaneously, the parameters associated with the uptake of C 4 by the mucosa (C 4 uptake and C 4 uptake ratio) were significantly lower in the DSS-acute rats than in the control group. Moreover, the acute inflamed mucosa seemed to utilize the digestive C 4 differently than the healthy one because the ⌬ 13 CO 2 enrichment (APE ϫ 100) was significantly lower in DSS-acute rats than in controls ( Table 4) . Portal flux of 12 CO 2 was not modified between DSS-acute (187.58 Ϯ 17.79 mol/min) and control rats (167.65 Ϯ 28.42 mol/min).
Chronic colitis. The calculated digestive 12 C 4 flux did not differ among the groups by time of killing. However, values of digestive 12 C 4 flux were higher in rats fed the RS diet than in rats fed the BD diet (as expected) regardless of the treatment: 1.80 Ϯ 0.60 and 0.77 Ϯ 0.16 mol/min) in RS and BD control groups (P ϭ 0.048), 2.65 Ϯ 0.58 and 1.32 Ϯ 0.31 mol/min) in RS-DSS and BD-DSS groups, respectively (P ϭ 0.011).
Contrary to what occurred during acute colitis, C 4 metabolism did not differ between controls and chronically inflamed rats. Results of ⌬ 13 C 4 portal flux did not differ between DSSchronic 7 (and 14) groups and corresponding control groups with either the BD or the RS diet (Table 5) . In all cases, the colonic mucosa utilized between 67 and 85 g/100 g of the available C 4 . The C 4 uptake values (which refer to the uptake of C 4 independently of the amount of available C 4 ) tended to be higher in RS-DSS chronic 14 rats than in corresponding controls (P ϭ 0.069). Interestingly, C 4 uptake values were significantly higher in RS-DSS chronic 14 than in BD-DSS chronic 14 rats (Table 5) .
During the phase of chronic colitis, the oxidation of C 4 into CO 2 did not differ between the DSS and control groups (Table  5 ) except for the RS-DSS chronic 14 groups in which ⌬ 13 CO 2 tended to be higher in inflamed rats (P ϭ 0.061).
Substantial heterogeneity was observed in the KB arteriovenous differences within groups. Nevertheless, the ratio of portal 13 C-enriched AA to 13 C-enriched BHB (singly and doubly labeled molecules) was nearly 3 and did not differ between DSS rats (2.93 Ϯ 0.46) and control rats (3.65 Ϯ 0.56) or between rats fed the BD (3.48 Ϯ 0.48) and the RS diet (3.01 Ϯ 0.54).
The ratio of 13 C-enriched KB (the sum of singly and doubly labeled KB) to 13 CO 2 portal concentrations in DSS-acute rats (1.52 Ϯ 0.28) did not differ from control rats (1.08 Ϯ 0.11). It also did not differ between the RS-DSS (1.45 Ϯ 0.23) and RS-control (2.55 Ϯ 0.67) or between the BD-DSS (1.77 Ϯ 0.60) and BD-control (2.54 Ϯ 0.52) groups.
DISCUSSION
Many factors are involved in the pathogenesis of UC. Among them, an inadequate uptake or an insufficient utilization of C 4 could be implicated. The effect of inflammation on the cecocolonic metabolism of C 4 is poorly documented in vivo. Consequently, we hypothesized that acute and chronic inflammatory lesions due to DSS would impair this metabolism. To confirm this, we infused [1-
13 C] C 4 into the cecum of rats, and 13 CO 2 and 13 C-enriched ketone bodies were quantified in portal blood to estimate C 4 colonic metabolism in DSS-treated or control rats.
During the study, at each instant, unlabeled butyrate was produced from bacterial fermentation in the intestinal lumen and rapidly absorbed by the mucosa. In our protocol, this system was not interrupted because cecum and blood vessels were not ligated.
The amount of infused tracer was determined according to the previously published values of the pool of cecal C 4 (26) . In that report, the mean amount of C 4 measured at the time of killing was in the range of 10 -15 mol for rats fed the basal diet and 30 -74 mol for rats fed the RS diet. Consequently, the [1-
13 C]-C 4 flux was fixed at 0.33 mol/min (that is, 20 mol of tracer infused in 1 h) to follow its utilization by the digestive mucosa and to obtain sufficient concentrations of labeled ketone bodies in the portal blood. Any isotope effect discriminating against labeled butyrate during butyrate transport across the mucosa was very unlikely. Thus, the ratio of 13 C-butyrate/ 12 C-butyrate measured in portal blood must reflect the 13 C-butyrate/ 12 C-butyrate in the cecal lumen. Because 13 C-butyrate/ 12 C-butyrate reached a steady state in portal blood, we therefore assumed that such a steady state also prevailed in the cecal lumen.
During the acute phase of the colitis, our results indicated a decrease in C 4 cecocolonic uptake. These data also agree with several in vitro studies, i.e., the mucosal metabolic flux of C 4 was decreased in an UC colonic biopsy (21) , and the absorption of C 4 by the proximal colon was inhibited during acute colitis in rabbits (34) . We also showed that ⌬ 13 CO 2 enrichment was lower in DSS-acute rats than in controls. Because portal flux of 12 CO 2 was not modified between DSSacute and control rats, we speculated that the decrease in APE was related more to a diminution of 13 C 4 oxidation to 13 CO 2 than to an effect of dilution by a higher production of portal 12 CO 2 in DSS rats. These results of a decrease in C 4 oxidation to CO 2 are similar to those obtained in isolated colonocytes of mice treated with DSS (22) , and in colonocytes isolated from acute UC patients (18) . The exhaled 14 CO 2 measured in acute UC patients after 14 C 4 enemas was also lower than that in healthy subjects (23) .
During the chronic colitis phase, C 4 uptake and CO 2 pro- duction did not differ between rats suffering from chronic colitis lesions and control rats. In the same way, there is no difference in the rate of rectal absorption of C 4 from dialysis bags in quiescent UC patients (35) . Conversely, a decrease in C 4 oxidation to CO 2 was observed in the colonic biopsy (20) and isolated colonocytes (18) from quiescent UC patients. This discrepancy between in vivo and in vitro studies could be explained by the difficulty in mimicking the physiologic conditions in in vitro models. The KB study did not allow us to characterize the possible effect of the inflammatory lesions on KB production with C 4 origin. The ratio of 13 C-enriched AA to 13 C-enriched ␤-hydroxy-butyrate (BHB) (singly and doubly labeled molecules) was nearly 3 regardless of the rat group. As observed in ruminants (36) , the AA to BHB ratio does not vary with the diet. The addition of C 4 to the cell culture medium of colonocytes isolated from healthy rats induces a higher in vitro production of AA than BHB (6, (37) (38) (39) and the ratio of AA to BHB can vary from 3 (22,40) to 5.5 (38) . Ratios of AA to BHB with C 4 origin of 1.9, 2.2, and 4.6 were observed in colonocytes isolated from food-deprived rats (38) , malnourished rats (38) , and DSS-inflamed mice (22) . KB production of C 4 origin was investigated in vivo in healthy rats after C 4 infusions into a cannulated colonic segment cleared of excess mucus and any remaining digesta (41, 42) . The authors noted that Ͼ50% of metabolized C 4 was incorporated into BHB, but AA was undetectable (41) . Our results refuted this statement and were in accordance with the in vitro AA:BHB ratio. The lack of AA detection by Fitch and Fleming (41) could be due to analytical reasons.
Our results showed a ratio of 13 C-labeled KB to 13 CO 2 of 2.25 Ϯ 0.35 in healthy rats (n ϭ 30). It was slightly higher than the ratios of 14 C-labeled KB: 14 CO 2 of 14 C 4 origin in the above-mentioned studies: 0.5, 0.8, and 1.4 using a 2 mmol/L, 10 mmol/L, or 40 mmol/L 14 C 4 perfusion (40 -60 min) solutions, respectively (41) . Increasing perfusion duration (60 -90 min) induced a 75% higher ratio using a 10 mmol/L 14 C 4 solution (42). In our study, a ratio of ϳ2.25 was obtained using a 20 mmol/L 13 C 4 infusion solution for 60 min, which agrees with a similar 75% increase in the ratio obtained with the 40 mmol/L solution during an infusion of shorter duration (41) . Additionally, under our experimental conditions, neither acute nor chronic DSS inflammation affected the ratio of 13 C-labeled KB to 13 CO 2 . In the present study, we showed that C 4 colonic uptake decreased during acute colitis, thus reducing the energy contribution available for the colonocytes. This can lead to cellular effects such as cell maturation impairment (18) , decrease of mucus synthesis (18) , lipogenesis, and cell membrane assembly (9), consequently disturbing the integrity of the mucosa.
By supplementing the diet with RS for 14 d, the uptake of C 4 by the inflamed mucosa was higher than in rats fed BD, providing a priori a higher energy supply to the mucosa. Our data also indicated that the digestive pool of C 4 measured at the time of killing was significantly higher in DSS-chronic 7 and chronic 14 rats fed the RS diet than in DSS rats fed the basal diet. These results agree with those observed in our previous study (26) . In spite of a higher C 4 cecocolonic disposal in RS-DSS rats compared with BD-DSS rats, this study showed that the C 4 uptake stimulation was observed only after 14 d.
Moreover, using macroscopic markers associated with double-blind histological analysis, we showed in a previous study the healing properties of the RS supplementation on the DSS injuries (26) . Major healing signs were present macroscopically and histologically in DSS rats after as little as 7 d of RS supplementation, with confirmation of these improvements after 14 d (26) . The RS healing effect was confirmed in the present study using the macroscopic score (Fig. 3) .
The improvement of the C 4 uptake by the inflamed mucosa appeared after 14 d of RS supplementation, whereas the first signs of mucosal healing were observed after as little as 7 d of RS treatment. First, this seems to indicate that the inflamed colonic epithelium has to be sufficiently healed to utilize the available digestive C 4 efficiently. Second, this suggests that the improvement of the C 4 uptake by the inflamed mucosa could not be a primary event but a consequence of the healing effect of RS. Consequently, the beneficial properties of dietary fiber (digestive 12 C 4 ϩ 13 C 4 flux ϩ infused 13 C 4 flux) .
yielding large amount of C 4 after fermentation, such as RS, may not be obviously related to a C 4 direct action via its colonic metabolization. The role of C 4 on the immune system (inhibition of nuclear fraction-B binding activity, for example) as well as the interactions between bacterial population and dietary substrate appear to be two more convincing hypotheses to explain the anti-inflammatory properties of those dietary fibers (43, 44) . Interactions between bacterial populations and dietary substrates appear to comprise another potential hypothesis. Indeed, RS ingestion stimulates the growth of lactic-acid bacteria (45, 46) , which were reported to inhibit sulfate-reducing bacteria particularly involved in the pathogenesis of UC (39, 47) . Sulfate-reducing bacteria generate high levels of sulfides, sulfites, and mercaptans, and some of these compounds are known to inhibit in vitro C 4 oxidation (48) and C 4 uptake by isolated colonocytes (49, 50) . Interactions between RS and lactic-acid bacteria could therefore be one of the mechanisms involved in the healing action of RS.
In conclusion, because the consequences of cecocolonic inflammation on C 4 metabolism cannot be predicted from conflicting in vitro data, we developed a model for this study under in vivo conditions, using stable isotopes infusion methods. Our results indicated a decrease in colonic C 4 uptake and lower oxidation of C 4 to CO 2 in rats suffering from DSS acute colitis compared with control rats. During chronic colitis, a normalization of both uptake of C 4 and its oxidation to CO 2 was observed. After 7 d of RS supplementation, in spite of a higher C 4 cecocolonic disposal, chronically inflamed rats fed the RS diet had the same C 4 uptake as rats fed the basal diet, whereas this uptake was higher after 14 d of RS supplementation. However, this increase in uptake was observed only after 14 d of RS treatment, which is later than the appearance of the histological evidence of the RS healing effect. The improvement of the colonic ability to utilize C 4 appeared to be a consequence of rather than an explanation for the RS action.
